Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - erlotinib hydrochloride - oral tablet - 150mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - erlotinib hydrochloride - oral tablet - 25mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - erlotinib hydrochloride - oral tablet - 150mg

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

genentech, inc. - erlotinib hydrochloride (unii: da87705x9k) (erlotinib - unii:j4t82ndh7e) - erlotinib 25 mg - tarceva® is indicated for:     •    the treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen [see clinical studies (14.1, 14.3)]. limitations of use:     •    safety and efficacy of tarceva have not been established in patients with nsclc whose tumors have other egfr mutations [see clinical studies (14.1, 14.2)].     •    tarceva is not recommended for use in combination with platinum-based chemotherapy [see clinical studies (14.4)] . tarceva in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer [see clinical studies (14.5)] . none. risk summary based on animal data and its mechanism of action, tarc

Belgia - angielski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - erlotinib hydrochloride 27,32 mg - eq. erlotinib 25 mg - film-coated tablet - 25 mg - erlotinib hydrochloride 27.32 mg - erlotinib

Belgia - angielski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - erlotinib hydrochloride 54,63 mg - eq. erlotinib 50 mg - film-coated tablet - 50 mg - erlotinib hydrochloride 54.63 mg - erlotinib

Belgia - angielski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - erlotinib hydrochloride 163,9 mg - eq. erlotinib 150 mg - film-coated tablet - 150 mg - erlotinib hydrochloride 163.9 mg - erlotinib

Belgia - angielski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - erlotinib hydrochloride 27,32 mg - eq. erlotinib 25 mg - film-coated tablet - 25 mg - erlotinib hydrochloride 27.32 mg - erlotinib

Belgia - angielski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - erlotinib hydrochloride 163,9 mg - eq. erlotinib 150 mg - film-coated tablet - 150 mg - erlotinib hydrochloride 163.9 mg - erlotinib

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - erlotinib hydrochloride - oral tablet - 150mg